0 XP   0   0   0

Allergy Therapeutics










Financial Health of Allergy Therapeutics




Comparing to competitors in the Drug Manufacturers-Specialty & Generic industry




  Industry Rankings  


Allergy Therapeutics
Buy, Hold or Sell?

Should you buy, hold or sell Allergy Therapeutics?

I guess you are interested in Allergy Therapeutics. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse Allergy Therapeutics

Let's start. I'm going to help you getting a better view of Allergy Therapeutics. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is Allergy Therapeutics even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how Allergy Therapeutics is doing in the market. If the company is worth buying. The latest step is to find out how other investors value Allergy Therapeutics. The closing price on 2022-12-02 was p13.25 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
Allergy Therapeutics Daily Candlestick Chart

Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

1.1. Profitability of Allergy Therapeutics.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Allergy Therapeutics earns for each 1 of revenue.

  • Above 10% is considered healthy but always compare Allergy Therapeutics to the Drug Manufacturers-Specialty & Generic industry mean.
  • A Net Profit Margin of 0.0% means that 0.00 for each 1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Allergy Therapeutics:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.8%+0.8%
TTM-5Y6.0%-6.0%
5Y6.0%10Y3.5%+2.5%
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.4%-0.4%
TTM-0.3%-0.3%
YOY-0.8%0.2%-1.0%
5Y6.0%-0.7%+6.7%
10Y3.5%-0.1%+3.6%
1.1.2. Return on Assets

Shows how efficient Allergy Therapeutics is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Allergy Therapeutics to the Drug Manufacturers-Specialty & Generic industry mean.
  • -13.9% Return on Assets means that Allergy Therapeutics generated -0.14 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Allergy Therapeutics:

  • The MRQ is -13.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -4.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-13.9%TTM-4.4%-9.5%
TTM-4.4%YOY-0.7%-3.7%
TTM-4.4%5Y1.3%-5.7%
5Y1.3%10Y1.2%+0.1%
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ-13.9%0.1%-14.0%
TTM-4.4%0.1%-4.5%
YOY-0.7%-0.1%-0.6%
5Y1.3%-0.2%+1.5%
10Y1.2%0.1%+1.1%
1.1.3. Return on Equity

Shows how efficient Allergy Therapeutics is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Allergy Therapeutics to the Drug Manufacturers-Specialty & Generic industry mean.
  • -26.6% Return on Equity means Allergy Therapeutics generated -0.27 for each 1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Allergy Therapeutics:

  • The MRQ is -26.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -8.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-26.6%TTM-8.1%-18.6%
TTM-8.1%YOY-1.4%-6.7%
TTM-8.1%5Y1.9%-9.9%
5Y1.9%10Y1.8%+0.0%
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ-26.6%0.6%-27.2%
TTM-8.1%0.4%-8.5%
YOY-1.4%0.4%-1.8%
5Y1.9%-0.3%+2.2%
10Y1.8%0.1%+1.7%

1.2. Operating Efficiency of Allergy Therapeutics.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Allergy Therapeutics is operating .

  • Measures how much profit Allergy Therapeutics makes for each 1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Allergy Therapeutics to the Drug Manufacturers-Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated 0.00  for each 1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Allergy Therapeutics:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY1.5%-1.5%
TTM-5Y7.0%-7.0%
5Y7.0%10Y3.1%+3.9%
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.5%-2.5%
TTM-1.6%-1.6%
YOY1.5%2.7%-1.2%
5Y7.0%1.8%+5.2%
10Y3.1%0.8%+2.3%
1.2.2. Operating Ratio

Measures how efficient Allergy Therapeutics is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers-Specialty & Generic industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are 0.00 for each 1 in net sales.

Let's take a look of the Operating Ratio trends of Allergy Therapeutics:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY0.363-0.363
TTM-5Y0.679-0.679
5Y0.67910Y0.794-0.115
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.473-1.473
TTM-1.456-1.456
YOY0.3631.398-1.035
5Y0.6791.374-0.695
10Y0.7941.191-0.397

1.3. Liquidity of Allergy Therapeutics.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Allergy Therapeutics is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers-Specialty & Generic industry mean).
  • A Current Ratio of 2.38 means the company has 2.38 in assets for each 1 in short-term debts.

Let's take a look of the Current Ratio trends of Allergy Therapeutics:

  • The MRQ is 2.381. The company is able to pay all its short-term debts. +1
  • The TTM is 3.091. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ2.381TTM3.091-0.709
TTM3.091YOY3.701-0.611
TTM3.0915Y2.781+0.309
5Y2.78110Y2.139+0.642
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ2.3811.880+0.501
TTM3.0911.901+1.190
YOY3.7012.112+1.589
5Y2.7812.182+0.599
10Y2.1391.891+0.248
1.3.2. Quick Ratio

Measures if Allergy Therapeutics is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Allergy Therapeutics to the Drug Manufacturers-Specialty & Generic industry mean.
  • A Quick Ratio of 1.48 means the company can pay off 1.48 for each 1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Allergy Therapeutics:

  • The MRQ is 1.484. The company is able to pay all its short-term debts with the most liquid assets. +1
  • The TTM is 1.402. The company is able to pay all its short-term debts with the most liquid assets. +1
Trends
Current periodCompared to+/- 
MRQ1.484TTM1.402+0.083
TTM1.402YOY1.747-0.345
TTM1.4025Y1.094+0.308
5Y1.09410Y0.870+0.224
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4840.733+0.751
TTM1.4020.796+0.606
YOY1.7470.808+0.939
5Y1.0940.834+0.260
10Y0.8700.821+0.049

1.4. Solvency of Allergy Therapeutics.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Allergy Therapeutics assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Allergy Therapeutics to Drug Manufacturers-Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.48 means that Allergy Therapeutics assets are financed with 47.8% credit (debt) and the remaining percentage (100% - 47.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Allergy Therapeutics:

  • The MRQ is 0.478. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.433. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.478TTM0.433+0.045
TTM0.433YOY0.439-0.006
TTM0.4335Y0.440-0.007
5Y0.44010Y0.419+0.021
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4780.437+0.041
TTM0.4330.424+0.009
YOY0.4390.398+0.041
5Y0.4400.398+0.042
10Y0.4190.401+0.018
1.4.2. Debt to Equity Ratio

Measures if Allergy Therapeutics is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Allergy Therapeutics to the Drug Manufacturers-Specialty & Generic industry mean.
  • A Debt to Equity ratio of 91.6% means that company has 0.92 debt for each 1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Allergy Therapeutics:

  • The MRQ is 0.916. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.769. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.916TTM0.769+0.147
TTM0.769YOY0.789-0.020
TTM0.7695Y0.799-0.030
5Y0.79910Y0.740+0.059
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9160.652+0.264
TTM0.7690.675+0.094
YOY0.7890.623+0.166
5Y0.7990.684+0.115
10Y0.7400.697+0.043

2. Market Valuation of Allergy Therapeutics

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every 1 in earnings Allergy Therapeutics generates.

  • Above 15 is considered overpriced but always compare Allergy Therapeutics to the Drug Manufacturers-Specialty & Generic industry mean.
  • A PE ratio of -13.78 means the investor is paying -13.78 for every 1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Allergy Therapeutics:

  • The EOD is -8.801. Company is losing money. -2
  • The MRQ is -13.783. Company is losing money. -2
  • The TTM is 27.739. Very good. +2
Trends
Current periodCompared to+/- 
EOD-8.801MRQ-13.783+4.982
MRQ-13.783TTM27.739-41.522
TTM27.739YOY-5.545+33.284
TTM27.7395Y229.375-201.636
5Y229.37510Y14,361.009-14,131.634
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
EOD-8.801-0.124-8.677
MRQ-13.783-0.437-13.346
TTM27.739-0.102+27.841
YOY-5.54515.340-20.885
5Y229.3757.916+221.459
10Y14,361.0097.700+14,353.309

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Allergy Therapeutics is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers-Specialty & Generic industry mean).
  • A PB ratio of 3.67 means the investor is paying 3.67 for each 1 in book value.

Let's take a look of the Price to Book Ratio trends of Allergy Therapeutics:

  • The EOD is 2.343. Good. +1
  • The MRQ is 3.670. Neutral. Compare to industry.
  • The TTM is 4.028. Neutral. Compare to industry.
Trends
Current periodCompared to+/- 
EOD2.343MRQ3.670-1.326
MRQ3.670TTM4.028-0.358
TTM4.028YOY2.544+1.484
TTM4.0285Y3.459+0.569
5Y3.45910Y4.205-0.745
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
EOD2.3431.415+0.928
MRQ3.6701.586+2.084
TTM4.0282.019+2.009
YOY2.5442.230+0.314
5Y3.4591.895+1.564
10Y4.2051.505+2.700
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Allergy Therapeutics compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---2.441-0.373-85%0.175-1495%0.054-4622%0.073-3443%
Book Value Growth--0.9820.9870%0.988-1%0.988-1%0.988-1%
Book Value Per Share--5.6547.248-22%7.722-27%6.515-13%5.247+8%
Book Value Per Share Growth---0.432-0.079-82%0.011-3984%-0.012-97%-0.003-99%
Current Ratio--2.3813.091-23%3.701-36%2.781-14%2.139+11%
Debt To Asset Ratio--0.4780.433+10%0.439+9%0.440+9%0.419+14%
Debt To Equity Ratio--0.9160.769+19%0.789+16%0.799+15%0.740+24%
Dividend Per Share----0%-0%-0%-0%
Eps---1.505-0.507-66%0.106-1517%-0.002-100%0.005-28855%
Eps Growth---0.370-100%-0.1720%-70.2500%-400.6350%
Gross Profit Margin--1.0001.0000%0.120+736%-0.158+116%-16.943+1794%
Net Profit Margin----0%-0.0080%0.060-100%0.035-100%
Operating Margin----0%0.015-100%0.070-100%0.031-100%
Operating Ratio----0%0.363-100%0.679-100%0.794-100%
Pb Ratio2.343-57%3.6704.028-9%2.544+44%3.459+6%4.205-13%
Pe Ratio-8.801+36%-13.78327.739-150%-5.545-60%229.375-106%14361.009-100%
Price Per Share13.250-57%20.75029.125-29%19.375+7%20.495+1%19.772+5%
Price To Total Gains Ratio-5.428+36%-8.50112.756-167%-4.551-46%3.227-363%2.785-405%
Profit Growth---98.7701.011-9874%-0.952-99%-47.701-52%-447.337+353%
Quick Ratio--1.4841.402+6%1.747-15%1.094+36%0.870+71%
Return On Assets---0.139-0.044-68%-0.007-95%0.013-1209%0.012-1266%
Return On Equity---0.266-0.081-70%-0.014-95%0.019-1538%0.018-1573%
Total Gains Per Share---2.441-0.373-85%0.175-1495%0.054-4622%0.073-3443%
Total Gains Per Share Growth---1.000--100%--100%--100%0.100-1100%
Usd Book Value--47212951.20060520912.000-22%64484527.600-27%54400016.661-13%43815771.333+8%
Usd Book Value Change Per Share---0.030-0.005-85%0.002-1495%0.001-4622%0.001-3443%
Usd Book Value Per Share--0.0700.089-22%0.095-27%0.080-13%0.065+8%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.019-0.006-66%0.001-1517%0.000-100%0.000-28855%
Usd Price Per Share0.163-57%0.2550.358-29%0.238+7%0.252+1%0.243+5%
Usd Profit---12570815.600-4234742.400-66%-422982.400-97%1369479.296-1018%913415.020-1476%
Usd Revenue----0%31933326.800-100%20284559.772-100%16278570.524-100%
Usd Total Gains Per Share---0.030-0.005-85%0.002-1495%0.001-4622%0.001-3443%
 EOD+3 -2MRQTTM+4 -22YOY+4 -255Y+5 -2510Y+11 -19

3.2. Fundamental Score

Let's check the fundamental score of Allergy Therapeutics based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-8.801
Price to Book Ratio (EOD)Between0-12.343
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.484
Current Ratio (MRQ)Greater than12.381
Debt to Asset Ratio (MRQ)Less than10.478
Debt to Equity Ratio (MRQ)Less than10.916
Return on Equity (MRQ)Greater than0.15-0.266
Return on Assets (MRQ)Greater than0.05-0.139
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Allergy Therapeutics based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5028.736
Ma 20Greater thanMa 5014.548
Ma 50Greater thanMa 10016.326
Ma 100Greater thanMa 20017.706
OpenGreater thanClose13.250
Total0/5 (0.0%)



Latest Balance Sheet

Balance Sheet of 2022-06-30. Currency in GBP. All numbers in thousands.

Summary
Total Assets73,580
Total Liabilities35,183
Total Stockholder Equity38,397
 As reported
Total Liabilities 35,183
Total Stockholder Equity+ 38,397
Total Assets = 73,580

Assets

Total Assets73,580
Total Current Assets42,393
Long-term Assets42,393
Total Current Assets
Cash And Cash Equivalents 20,515
Net Receivables 5,905
Inventory 11,410
Total Current Assets  (as reported)42,393
Total Current Assets  (calculated)37,830
+/- 4,563
Long-term Assets
Property Plant Equipment 20,190
Goodwill 3,347
Intangible Assets 1,688
Other Assets 5,962
Long-term Assets  (as reported)31,187
Long-term Assets  (calculated)31,187
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities17,801
Long-term Liabilities17,382
Total Stockholder Equity38,397
Total Current Liabilities
Short-term Debt 2,016
Short Long Term Debt 952
Accounts payable 15,669
Other Current Liabilities 116
Total Current Liabilities  (as reported)17,801
Total Current Liabilities  (calculated)18,753
+/- 952
Long-term Liabilities
Capital Lease Obligations 8,080
Other Liabilities 8,869
Long-term Liabilities  (as reported)17,382
Long-term Liabilities  (calculated)16,949
+/- 433
Total Stockholder Equity
Common Stock644
Retained Earnings -117,910
Other Stockholders Equity 155,663
Total Stockholder Equity (as reported)38,397
Total Stockholder Equity (calculated)38,397
+/-0
Other
Capital Stock644
Cash and Short Term Investments 20,515
Common Stock Shares Outstanding 644,105
Liabilities and Stockholders Equity 73,580
Net Debt -9,986
Net Invested Capital 40,846
Net Tangible Assets 33,362
Net Working Capital 24,592
Short Long Term Debt Total 10,529



Balance Sheet

Currency in GBP. All numbers in thousands.

 Trend2022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312020-01-312019-12-312019-09-302019-06-302019-03-312019-01-312018-12-312018-09-302018-06-302018-03-312018-01-312017-12-312017-09-302017-06-302017-03-312017-01-312016-12-312016-09-302016-06-302016-03-312016-01-312015-12-312015-09-302015-06-302015-03-312015-01-312014-12-312014-09-302014-06-302014-03-312014-01-312013-12-312013-09-302013-06-302013-03-312013-01-312012-12-312012-09-302012-06-302012-03-312012-01-312011-12-312011-09-302011-06-302011-03-312011-01-312010-12-312010-09-302010-06-302010-03-312010-01-312009-12-312009-09-302009-06-302009-03-312009-01-312008-12-312008-09-302008-06-302008-03-312008-01-312007-12-312007-09-302007-06-302007-03-312007-01-312006-12-312006-09-302006-06-302006-03-312006-01-312005-12-312005-09-302005-06-302005-03-312005-01-312004-12-312004-09-302004-06-302004-03-312004-01-312003-12-312003-09-302003-06-302003-03-312003-01-312002-09-302002-06-302002-03-312002-01-31
> Total Assets 
0
0
0
0
0
0
11,149
0
14,205
0
11,234
11,234
29,040
29,040
0
26,660
26,660
23,968
23,968
0
37,880
37,880
0
32,642
0
23,994
23,994
23,600
27,195
0
23,183
23,183
28,646
28,646
0
22,077
22,077
33,502
33,502
0
29,115
29,115
34,177
34,177
0
30,621
30,621
33,077
33,077
0
27,754
27,754
33,006
33,006
0
28,964
28,964
34,159
34,159
0
28,398
28,398
35,655
35,655
0
50,699
50,699
64,392
64,392
0
56,679
56,679
64,860
64,860
0
57,183
57,183
64,904
64,904
0
51,016
51,016
71,277
71,277
0
68,497
68,497
87,922
87,922
0
0
86,225
0
99,003
0
88,089
0
91,973
0
73,580
73,580091,973088,089099,003086,2250087,92287,92268,49768,497071,27771,27751,01651,016064,90464,90457,18357,183064,86064,86056,67956,679064,39264,39250,69950,699035,65535,65528,39828,398034,15934,15928,96428,964033,00633,00627,75427,754033,07733,07730,62130,621034,17734,17729,11529,115033,50233,50222,07722,077028,64628,64623,18323,183027,19523,60023,99423,994032,642037,88037,880023,96823,96826,66026,660029,04029,04011,23411,234014,205011,149000000
   > Total Current Assets 
0
0
0
0
0
0
0
0
8,587
0
0
5,567
0
23,251
0
0
20,981
0
18,177
0
0
31,088
0
23,892
0
0
14,043
0
16,043
0
0
11,317
0
15,568
0
0
9,442
0
19,018
0
0
14,804
0
18,562
0
0
14,914
0
17,746
0
0
13,034
0
19,057
0
0
14,458
0
19,707
0
0
14,211
0
21,702
0
0
33,789
0
47,176
0
0
37,612
45,441
45,441
0
37,459
37,459
45,144
45,144
0
30,928
30,928
50,999
50,999
0
46,625
46,625
57,534
57,534
0
55,170
55,170
69,155
69,155
57,858
57,858
63,090
63,090
42,393
42,393
42,39342,39363,09063,09057,85857,85869,15569,15555,17055,170057,53457,53446,62546,625050,99950,99930,92830,928045,14445,14437,45937,459045,44145,44137,6120047,176033,7890021,702014,2110019,707014,4580019,057013,0340017,746014,9140018,562014,8040019,01809,4420015,568011,3170016,043014,0430023,892031,0880018,177020,9810023,25105,567008,58700000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
3,165
0
0
1,457
0
17,234
0
0
15,080
0
10,912
0
0
23,860
0
15,204
0
0
5,696
0
5,752
0
0
2,298
0
3,013
0
0
0
0
5,286
0
0
4,520
0
2,285
0
0
1,048
0
1,960
0
0
903
0
3,513
0
0
1,257
0
5,214
0
0
2,029
0
7,985
0
0
21,199
0
33,206
0
0
23,406
27,763
27,763
0
22,122
22,122
25,812
25,812
0
15,533
15,533
31,642
31,642
0
27,440
27,440
39,725
39,725
0
0
36,962
0
48,289
0
40,273
0
41,385
0
20,515
20,515041,385040,273048,289036,9620039,72539,72527,44027,440031,64231,64215,53315,533025,81225,81222,12222,122027,76327,76323,4060033,206021,199007,98502,029005,21401,257003,5130903001,96001,048002,28504,520005,28600003,01302,298005,75205,6960015,204023,8600010,912015,0800017,23401,457003,16500000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
63
0
0
0
0
3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
483
0
24
0
0
2
0
68
0
0
345
0
163
0
0
783
0
3
0
0
0
0
0
0
0
404
0
384
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000003840404000000030783001630345006802002404830000000000000000000300006300000000000000000000000000
       Net Receivables 
0
0
0
0
0
0
1,127
0
0
0
2,063
2,063
3,832
3,832
0
2,812
2,812
4,023
4,023
0
2,482
2,482
0
4,852
0
2,651
2,651
3,400
4,277
0
2,699
2,699
6,490
6,490
0
2,284
2,284
6,701
6,701
0
2,663
2,663
8,940
8,940
0
5,746
5,746
8,663
8,663
0
3,761
3,761
9,222
9,222
0
5,421
5,404
8,270
8,270
0
4,387
4,387
7,236
7,236
0
4,230
4,230
7,141
7,141
0
5,517
5,517
10,653
10,653
0
6,271
6,271
10,939
10,939
0
5,405
5,405
10,324
10,324
0
8,492
4,373
8,769
8,769
0
5,835
5,835
10,772
10,772
4,618
4,618
10,773
10,773
5,905
5,905
5,9055,90510,77310,7734,6184,61810,77210,7725,8355,83508,7698,7694,3738,492010,32410,3245,4055,405010,93910,9396,2716,271010,65310,6535,5175,51707,1417,1414,2304,23007,2367,2364,3874,38708,2708,2705,4045,42109,2229,2223,7613,76108,6638,6635,7465,74608,9408,9402,6632,66306,7016,7012,2842,28406,4906,4902,6992,69904,2773,4002,6512,65104,85202,4822,48204,0234,0232,8122,81203,8323,8322,0632,0630001,127000000
       Other Current Assets 
0
0
0
0
0
0
1,187
0
0
0
222
222
0
0
0
348
348
0
0
0
1,095
1,095
0
0
0
722
722
0
0
0
500
500
0
0
0
1,156
1,156
0
0
0
727
727
0
0
0
1,033
1,033
278
278
0
1,236
1,236
24
24
0
1,764
1,781
68
68
0
981
981
163
163
0
830
830
3
3
0
997
997
0
0
0
1,582
1,582
0
0
0
1,182
1,182
0
0
0
0
0
324
9,093
0
0
8,076
2
10,774
525
6,747
330
11,103
0
10,468
10,468011,1033306,74752510,77428,076009,093324000001,1821,1820001,5821,5820009979970338308300163163981981068681,7811,764024241,2361,23602782781,0331,0330007277270001,1561,1560005005000007227220001,0951,0950003483480002222220001,187000000
   > Long-term Assets 
0
0
0
0
0
0
0
0
5,618
0
0
5,667
0
5,789
0
0
5,679
0
5,791
0
0
6,792
0
8,750
0
0
9,951
0
11,152
0
0
11,866
0
13,078
0
0
12,635
0
14,484
0
0
14,311
0
15,615
0
0
15,707
0
15,331
0
0
14,720
0
13,949
0
0
14,506
0
14,452
0
0
14,187
0
13,953
0
0
16,910
0
17,216
0
0
19,067
0
19,419
0
0
19,724
0
19,760
0
0
20,088
0
20,278
0
0
21,872
0
30,388
0
0
31,055
0
29,848
0
30,231
0
28,883
0
31,187
31,187028,883030,231029,848031,0550030,388021,8720020,278020,0880019,760019,7240019,419019,0670017,216016,9100013,953014,1870014,452014,5060013,949014,7200015,331015,7070015,615014,3110014,484012,6350013,078011,8660011,15209,951008,75006,792005,79105,679005,78905,667005,61800000000
       Property Plant Equipment 
0
0
0
0
0
0
1,221
0
1,293
0
1,650
1,650
1,926
1,926
0
2,111
2,111
2,414
2,414
0
3,637
3,637
0
4,771
0
5,486
5,931
6,900
6,902
0
6,883
6,883
7,260
7,260
0
7,191
7,191
8,772
8,772
0
8,938
8,938
8,971
8,971
0
8,809
8,809
8,147
8,147
0
7,555
7,555
7,317
7,317
0
7,337
7,337
7,147
7,147
0
7,030
7,030
6,785
6,785
0
8,750
8,750
8,787
8,787
0
9,667
9,667
9,708
9,708
0
9,673
9,673
9,798
9,798
0
10,096
10,096
10,034
10,034
0
11,481
11,481
20,340
20,340
0
20,417
20,417
19,503
19,503
19,717
19,717
18,992
18,992
20,190
20,190
20,19020,19018,99218,99219,71719,71719,50319,50320,41720,417020,34020,34011,48111,481010,03410,03410,09610,09609,7989,7989,6739,67309,7089,7089,6679,66708,7878,7878,7508,75006,7856,7857,0307,03007,1477,1477,3377,33707,3177,3177,5557,55508,1478,1478,8098,80908,9718,9718,9388,93808,7728,7727,1917,19107,2607,2606,8836,88306,9026,9005,9315,48604,77103,6373,63702,4142,4142,1112,11101,9261,9261,6501,65001,29301,221000000
       Goodwill 
0
0
0
0
0
0
3,220
0
0
0
2,945
2,945
2,850
2,850
0
2,617
2,617
2,484
2,484
0
2,326
4,977
0
2,296
0
2,295
2,295
0
2,380
0
2,468
2,468
2,735
2,735
0
2,555
2,555
2,627
2,627
0
2,496
2,496
2,564
2,564
0
2,624
2,624
2,536
2,536
0
2,489
2,489
2,489
2,489
0
2,560
2,560
2,531
2,531
0
2,480
2,480
2,454
2,454
0
2,980
2,980
3,053
3,053
0
3,271
3,271
3,382
3,382
0
3,390
3,390
3,412
3,412
0
3,406
3,406
3,438
3,438
0
3,432
3,432
3,324
3,324
0
0
3,467
0
3,438
0
3,343
0
3,374
0
3,347
3,34703,37403,34303,43803,467003,3243,3243,4323,43203,4383,4383,4063,40603,4123,4123,3903,39003,3823,3823,2713,27103,0533,0532,9802,98002,4542,4542,4802,48002,5312,5312,5602,56002,4892,4892,4892,48902,5362,5362,6242,62402,5642,5642,4962,49602,6272,6272,5552,55502,7352,7352,4682,46802,38002,2952,29502,29604,9772,32602,4842,4842,6172,61702,8502,8502,9452,9450003,220000000
       Intangible Assets 
0
0
0
0
0
0
4,432
0
4,325
0
4,017
4,017
3,863
3,863
0
3,568
951
3,377
893
0
3,155
-1,822
0
773
0
3,454
1,159
2,700
653
0
3,541
1,073
3,902
1,167
0
3,620
1,065
3,605
978
0
3,356
860
4,337
1,773
0
4,405
1,781
4,711
2,175
0
4,596
2,107
3,821
1,332
0
3,910
1,350
3,935
1,404
0
3,771
1,291
3,646
1,192
0
5,000
2,020
4,978
1,925
0
5,355
2,084
5,420
2,038
0
5,459
2,069
5,108
1,696
0
1,543
1,543
1,437
1,437
0
1,408
1,408
1,245
1,245
0
0
1,269
0
980
0
1,411
0
791
0
1,688
1,688079101,411098001,269001,2451,2451,4081,40801,4371,4371,5431,54301,6965,1082,0695,45902,0385,4202,0845,35501,9254,9782,0205,00001,1923,6461,2913,77101,4043,9351,3503,91001,3323,8212,1074,59602,1754,7111,7814,40501,7734,3378603,35609783,6051,0653,62001,1673,9021,0733,54106532,7001,1593,45407730-1,8223,15508933,3779513,56803,8633,8634,0174,01704,32504,432000000
       Other Assets 
0
0
0
0
0
0
4,432
0
0
0
4,017
4,017
3,863
3,863
0
3,568
3,568
3,377
3,377
0
3,155
3,155
0
2,905
0
4,465
3,692
2,700
4,250
0
4,983
4,983
5,818
5,818
0
5,444
5,444
5,712
5,712
0
5,373
5,373
6,644
6,644
0
6,898
6,898
7,184
7,184
0
7,165
7,165
6,632
6,632
0
7,169
7,169
7,305
7,305
0
7,157
7,157
7,168
7,168
0
8,160
8,160
8,429
8,429
0
9,400
9,400
9,711
9,711
0
10,051
10,051
9,962
9,962
0
5,043
5,043
5,369
5,369
0
5,551
5,551
5,479
5,479
0
5,902
5,902
5,927
5,927
5,760
5,760
5,726
5,726
5,962
5,962
5,9625,9625,7265,7265,7605,7605,9275,9275,9025,90205,4795,4795,5515,55105,3695,3695,0435,04309,9629,96210,05110,05109,7119,7119,4009,40008,4298,4298,1608,16007,1687,1687,1577,15707,3057,3057,1697,16906,6326,6327,1657,16507,1847,1846,8986,89806,6446,6445,3735,37305,7125,7125,4445,44405,8185,8184,9834,98304,2502,7003,6924,46502,90503,1553,15503,3773,3773,5683,56803,8633,8634,0174,0170004,432000000
> Total Liabilities 
0
0
0
0
0
0
4,988
0
4,779
0
4,158
4,158
4,260
4,260
0
6,576
6,576
4,237
4,237
0
5,178
5,178
0
7,983
0
15,398
15,398
15,200
24,996
0
34,473
34,473
48,053
48,053
0
45,253
45,253
25,018
25,018
0
25,229
25,229
23,918
23,918
0
28,482
28,482
22,611
22,611
0
13,162
13,162
13,042
13,042
0
14,293
14,293
12,839
12,839
0
13,323
13,323
14,167
14,167
0
16,230
16,230
17,672
17,672
0
26,355
26,355
26,397
26,397
0
27,218
27,218
29,003
29,003
0
27,982
27,982
26,800
26,800
0
30,939
30,939
36,719
36,719
0
0
42,442
0
40,275
0
39,554
0
36,999
0
35,183
35,183036,999039,554040,275042,4420036,71936,71930,93930,939026,80026,80027,98227,982029,00329,00327,21827,218026,39726,39726,35526,355017,67217,67216,23016,230014,16714,16713,32313,323012,83912,83914,29314,293013,04213,04213,16213,162022,61122,61128,48228,482023,91823,91825,22925,229025,01825,01845,25345,253048,05348,05334,47334,473024,99615,20015,39815,39807,98305,1785,17804,2374,2376,5766,57604,2604,2604,1584,15804,77904,988000000
   > Total Current Liabilities 
0
0
0
0
0
0
3,997
0
4,319
0
3,277
3,277
3,801
3,801
0
6,121
6,121
4,011
4,011
0
4,939
4,939
0
5,329
0
10,864
10,864
0
7,170
0
8,105
8,105
15,942
15,942
0
21,774
21,774
8,829
8,829
0
9,984
9,984
10,407
10,407
0
11,147
11,147
11,742
11,742
0
7,747
7,747
7,608
7,608
0
7,620
7,620
6,436
6,436
0
6,474
6,474
6,276
6,276
0
7,420
7,420
8,168
8,168
0
12,520
12,520
13,167
13,167
0
14,020
14,020
15,470
15,470
0
14,631
14,631
13,621
13,621
0
16,859
16,859
15,019
15,019
0
18,227
18,227
16,352
16,352
18,230
18,230
16,604
16,604
17,801
17,801
17,80117,80116,60416,60418,23018,23016,35216,35218,22718,227015,01915,01916,85916,859013,62113,62114,63114,631015,47015,47014,02014,020013,16713,16712,52012,52008,1688,1687,4207,42006,2766,2766,4746,47406,4366,4367,6207,62007,6087,6087,7477,747011,74211,74211,14711,147010,40710,4079,9849,98408,8298,82921,77421,774015,94215,9428,1058,10507,170010,86410,86405,32904,9394,93904,0114,0116,1216,12103,8013,8013,2773,27704,31903,997000000
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
278
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
452
0
0
2,422
0
6,545
0
0
11,652
0
681
0
0
1,109
0
2,116
0
0
2,793
0
3,153
0
0
0
0
114
0
0
288
0
95
0
0
49
0
49
0
0
251
0
262
0
0
295
3,377
306
0
3,327
391
395
395
0
644
644
664
664
0
694
694
659
2,116
0
0
2,264
0
2,200
0
1,755
0
1,662
0
2,016
2,01601,66201,75502,20002,264002,116659694694066466464464403953953913,32703063,3772950026202510049049009502880011400003,15302,793002,11601,10900681011,652006,54502,42200452000000000000000027800000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,377
3,377
0
3,327
3,327
395
395
0
644
644
664
664
0
694
694
659
659
0
0
829
0
800
0
963
0
1,008
0
952
95201,00809630800082900659659694694066466464464403953953,3273,32703,3773,377000000000000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
0
0
0
0
0
0
1,196
0
0
0
827
827
0
0
0
1,478
1,478
0
0
0
1,671
1,671
0
0
0
4,612
4,612
0
6,718
0
2,312
2,312
6,033
6,033
0
3,742
3,742
7,603
7,603
0
3,948
3,948
7,982
7,982
0
3,821
3,821
8,589
8,589
0
2,553
2,553
7,424
7,424
0
3,050
3,050
6,341
6,341
0
2,464
2,464
6,227
6,227
0
2,819
2,819
7,906
7,906
0
3,110
3,110
12,375
12,375
0
2,881
2,881
14,691
14,691
0
3,193
3,193
12,892
12,892
0
4,141
4,141
12,903
12,903
0
2,217
2,217
14,152
14,152
2,897
2,897
14,942
14,942
15,669
15,669
15,66915,66914,94214,9422,8972,89714,15214,1522,2172,217012,90312,9034,1414,141012,89212,8923,1933,193014,69114,6912,8812,881012,37512,3753,1103,11007,9067,9062,8192,81906,2276,2272,4642,46406,3416,3413,0503,05007,4247,4242,5532,55308,5898,5893,8213,82107,9827,9823,9483,94807,6037,6033,7423,74206,0336,0332,3122,31206,71804,6124,6120001,6711,6710001,4781,4780008278270001,196000000
       Other Current Liabilities 
0
0
0
0
0
0
2,301
0
0
0
2,172
2,172
3,801
3,801
0
4,643
4,643
4,011
4,011
0
3,268
3,268
0
5,329
0
6,252
6,102
0
0
0
3,371
3,371
3,364
3,364
0
6,380
6,380
545
545
0
4,927
4,927
309
309
0
4,533
4,533
0
0
0
3,768
3,768
70
70
0
4,282
4,282
0
0
0
3,961
3,961
0
0
0
4,350
4,350
0
0
0
9,115
9,115
486
486
0
10,748
10,748
384
384
0
309
309
65
65
0
561
561
0
0
0
887
13,746
0
0
25
9,824
0
0
116
116
116116009,824250013,74688700056156106565309309038438410,74810,74804864869,1159,1150004,3504,3500003,9613,9610004,2824,282070703,7683,7680004,5334,53303093094,9274,92705455456,3806,38003,3643,3643,3713,3710006,1026,25205,32903,2683,26804,0114,0114,6434,64303,8013,8012,1722,1720002,301000000
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
460
0
0
881
0
459
0
0
455
0
226
0
0
239
0
2,654
0
0
4,534
0
17,826
0
0
26,368
0
32,111
0
0
23,479
0
16,189
0
0
15,245
0
13,511
0
0
17,335
0
10,869
0
0
5,415
0
5,434
0
0
6,673
0
6,403
0
0
6,849
0
7,891
0
0
8,810
0
9,504
0
0
13,835
0
13,230
0
0
13,198
0
13,533
0
0
13,351
0
13,179
0
0
14,080
0
21,700
0
0
24,215
0
23,923
0
21,324
0
20,395
0
17,382
17,382020,395021,324023,923024,2150021,700014,0800013,179013,3510013,533013,1980013,230013,835009,50408,810007,89106,849006,40306,673005,43405,4150010,869017,3350013,511015,2450016,189023,4790032,111026,3680017,82604,534002,65402390022604550045908810046000000000
       Other Liabilities 
0
0
0
0
0
0
241
0
0
0
214
214
459
459
0
455
455
226
226
0
239
239
0
193
0
2,373
2,373
15,200
2,656
0
2,955
2,955
5,349
5,349
0
4,224
4,224
4,463
4,463
0
4,649
4,649
4,979
4,979
0
4,773
4,773
4,470
4,470
0
5,153
5,153
5,176
5,176
0
6,514
6,514
6,254
6,254
0
6,713
6,713
7,763
7,763
0
7,079
7,079
7,830
7,830
0
10,431
10,431
9,844
9,844
0
9,910
9,910
10,410
10,410
0
10,937
10,937
11,087
11,087
0
12,338
12,338
12,847
12,847
0
14,300
14,300
14,131
14,131
11,907
11,907
12,127
12,127
8,869
8,869
8,8698,86912,12712,12711,90711,90714,13114,13114,30014,300012,84712,84712,33812,338011,08711,08710,93710,937010,41010,4109,9109,91009,8449,84410,43110,43107,8307,8307,0797,07907,7637,7636,7136,71306,2546,2546,5146,51405,1765,1765,1535,15304,4704,4704,7734,77304,9794,9794,6494,64904,4634,4634,2244,22405,3495,3492,9552,95502,65615,2002,3732,3730193023923902262264554550459459214214000241000000
> Total Stockholder Equity
0
0
0
0
0
0
6,161
6,161
0
0
7,076
7,076
24,780
24,780
0
20,084
20,084
19,731
19,731
0
32,702
32,702
0
26,046
0
8,596
8,355
8,400
2,199
0
0
0
0
0
0
0
0
8,484
8,484
0
3,886
3,886
10,259
10,259
0
2,139
2,139
10,466
10,466
0
14,592
14,592
19,964
19,964
0
14,671
14,671
21,320
21,320
0
15,075
15,075
21,488
21,488
0
34,469
34,469
46,720
46,720
0
30,324
30,324
38,463
38,463
0
29,965
29,965
35,901
35,901
0
23,034
23,034
44,477
44,477
0
37,558
37,558
51,203
51,203
0
0
43,783
0
58,728
0
48,535
0
54,974
0
38,397
38,397054,974048,535058,728043,7830051,20351,20337,55837,558044,47744,47723,03423,034035,90135,90129,96529,965038,46338,46330,32430,324046,72046,72034,46934,469021,48821,48815,07515,075021,32021,32014,67114,671019,96419,96414,59214,592010,46610,4662,1392,139010,25910,2593,8863,88608,4848,484000000002,1998,4008,3558,596026,046032,70232,702019,73119,73120,08420,084024,78024,7807,0767,076006,1616,161000000
   Common Stock
0
0
0
0
0
0
51
0
0
0
51
51
73
73
0
63
63
73
73
0
82
82
0
92
0
82
82
33,300
92
0
82
82
92
92
0
82
82
303
303
0
311
311
321
321
0
311
311
321
321
0
407
407
420
420
0
410
410
420
420
0
410
410
420
420
0
546
546
597
597
0
589
589
603
603
0
594
594
604
604
0
596
596
646
646
0
636
636
646
646
0
637
637
651
651
641
641
652
652
644
644
64464465265264164165165163763706466466366360646646596596060460459459406036035895890597597546546042042041041004204204104100420420407407032132131131103213213113110303303828209292828209233,30082820920828207373636307373515100051000000
   Retained Earnings Total Equity0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 00000000-18,4160000-15,4410000-14,3440000-12,9030000-12,9970000-11,5180000-10,6240000-9,9030000-9,0130000-7,6890000-6,2590000-5,5470000-4,4730000-3,4630000-4,6320000-4,0260000-3,65200000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
112,576
0
112,576
0
0
112,576
0
112,576
0
112,576
0
0
0
0
0000112,5760112,5760112,57600112,5760112,57600000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
41,478
41,478
0
41,385
41,385
41,294
41,294
0
41,768
41,768
42,557
42,557
0
43,523
171,540
43,572
156,148
0
43,531
174,523
43,491
156,067
42,716
155,292
43,029
155,605
43,087
155,663
155,66343,087155,60543,029155,29242,716156,06743,491174,52343,5310156,14843,572171,54043,523042,55742,55741,76841,768041,29441,29441,38541,385041,47841,478000000000000000000000000000000000000000000000000000000000000000000000000



Balance Sheet

Currency in GBP. All numbers in thousands.